Literature DB >> 30130311

Endoscopy in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto IBD Group of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition.

Salvatore Oliva1, Mike Thomson2, Lissy de Ridder3, Javier Martín-de-Carpi4, Stephanie Van Biervliet5, Christian Braegger6, Jorge Amil Dias7, Sanja Kolacek8, Erasmo Miele9, Stephan Buderus10, Jiri Bronsky11, Harland Winter12, Víctor Manuel Navas-López13, Amit Assa14, Sonny K F Chong15, Nadeem Ahmad Afzal16, Francoise Smets17, Ron Shaoul18, Séamus Hussey19, Dan Turner20, Salvatore Cucchiara1.   

Abstract

Endoscopy is a central tool for the evaluation and management of inflammatory bowel disease (IBD). In the last few decades, gastrointestinal (GI) endoscopy has undergone significant technological developments including availability of pediatric-size equipment, enabling comprehensive investigation of the GI tract in children. Simultaneously, professional organization of GI experts have developed guidelines and training programs in pediatric GI endoscopy. This prompted the Porto Group on Pediatric IBD of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition to develop updated guidelines on the role of GI endoscopy in pediatric IBD, specifically taking into considerations of recent advances in the diagnosis, disease stratification, and novel therapeutic targets in these patients.

Entities:  

Mesh:

Year:  2018        PMID: 30130311     DOI: 10.1097/MPG.0000000000002092

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  8 in total

1.  Increased Demand for Therapeutic Drugs in Pediatric Ulcerative Colitis Patients With Extraintestinal Manifestations.

Authors:  Yiyoung Kwon; Eun Sil Kim; Yon Ho Choe; Mi Jin Kim
Journal:  Front Pediatr       Date:  2022-05-23       Impact factor: 3.569

2.  Partial enteral nutrition induces clinical and endoscopic remission in active pediatric Crohn's disease: results of a prospective cohort study.

Authors:  Darja Urlep; Evgen Benedik; Jernej Brecelj; Rok Orel
Journal:  Eur J Pediatr       Date:  2019-11-28       Impact factor: 3.183

3.  Serological cytokine signature in paediatric patients with inflammatory bowel disease impacts diagnosis.

Authors:  Maiko Tatsuki; Reiko Hatori; Tomoko Nakazawa; Takashi Ishige; Tomoko Hara; Seiichi Kagimoto; Takeshi Tomomasa; Hirokazu Arakawa; Takumi Takizawa
Journal:  Sci Rep       Date:  2020-09-03       Impact factor: 4.379

4.  Micronutrient Deficiencies and Anemia in Children with Inflammatory Bowel Disease.

Authors:  Julie Rempel; Kanika Grover; Wael El-Matary
Journal:  Nutrients       Date:  2021-01-15       Impact factor: 5.717

5.  Carbon Dioxide vs. Air Insufflation for Pediatric Gastrointestinal Endoscopy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Chunwang Ji; Xue Liu; Peng Huang
Journal:  Front Pediatr       Date:  2021-02-09       Impact factor: 3.418

6.  Evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric Crohn's disease.

Authors:  Maria M E Jongsma; Stephanie A Vuijk; Martinus A Cozijnsen; Merel van Pieterson; Obbe F Norbruis; Michael Groeneweg; Victorien M Wolters; Herbert M van Wering; Iva Hojsak; Kaija-Leena Kolho; Michiel P van Wijk; Sarah T A Teklenburg-Roord; Tim G J de Meij; Johanna C Escher; Lissy de Ridder
Journal:  Eur J Pediatr       Date:  2022-06-08       Impact factor: 3.860

7.  Simultaneous Assessment of Urinary and Fecal Volatile Organic Compound Analysis in De Novo Pediatric IBD.

Authors:  Sofia El Manouni El Hassani; Sofie Bosch; Jesse P M Lemmen; Marina Brizzio Brentar; Ibrahim Ayada; Alfian N Wicaksono; James A Covington; Marc A Benninga; Nanne K H de Boer; Tim G J de Meij
Journal:  Sensors (Basel)       Date:  2019-10-16       Impact factor: 3.576

8.  Eosinophilic esophagitis: when pathologists make the difference.

Authors:  Silvia Salvatore
Journal:  J Pediatr (Rio J)       Date:  2021-08-31       Impact factor: 2.990

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.